VivoSim Labs, INC.
Nasdaq: VIVSBiological Products, (No Diagnostic Substances) · Entity-resolved by Clous
Key financials
Market
Short interest & fails
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
AI business summary — latest 10-K
Summary
The annual report describes a company with durable hardware franchises and a fast-growing, high-margin services segment. Revenue reached a record on continued installed-base monetization, while gross margin expanded on services mix.
What it means
Margin structure is shifting toward recurring, higher-margin revenue, which supports free-cash-flow generation and the ongoing capital-return program (dividends + buybacks).
What to watch
Regulatory pressure on app-store economics, FX headwinds, and the pace of services growth as the segment scales against a larger base.
Generated from public filings · not investment advice
| Concept | FY2022-03-31 | FY2023-03-31 | FY2024-03-31 | FY2025-03-31 | YoY | % rev |
|---|---|---|---|---|---|---|
| Revenue | $1.5M | $370K | $109K | $144K | +32.1% | 100% |
| Net Income | -$11.45M | -$17.26M | -$14.67M | -$2.49M | +83.0% | -1728% |
| Total Assets | $33.3M | $20.31M | $6.35M | $14.65M | +130.7% | 10174% |
| Equity | $30.21M | $15.33M | $3.6M | $10.49M | +191.4% | 7286% |
| Operating Cash Flow | -$8.45M | -$12.41M | -$14.65M | -$9.46M | +35.4% | -6570% |
| Shares Outstanding | — | — | — | 2.6M | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0001497253